Komori
Earnings4928Noevir Holdings Co.,Ltd.Materials and Chemicals

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending September 2026 [Japanese GAAP] (Consolidated)

For the interim period of the fiscal year ending September 2026, net sales, operating income and ordinary income were below the year-earlier period, while interim net income attributable to owners of the parent increased. The full-year earnings forecasts and annual dividend forecast remain unchanged.

Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-20.6
%
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 October 2025–31 March 2026ConsolidatedJapanese GAAP
Net Sales30,615¥ millionYear on year -4.4%Progress 47.1%
Operating profit4,534¥ millionYear on year -20.6%Progress 39.8%
Ordinary income4,789¥ millionYear on year -20.5%Progress 40.6%
Net income attributable to owners of the parent2,718¥ millionYear on year +2.9%Progress 33.1%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥79.59
Financial position at period-end
Total assets71,736¥ million
of which net assets 49,489 ¥ millionEquity ratio 68.1%vs. prior year-end -2.2pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+3,080
Investment+1,063
Financials-7,895
Net change-3,752

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥23,215 million
Segment revenueCosmetics Business ¥24,173 million (YoY -5.0%), Pharmaceuticals and food business ¥5,385 million (YoY -3.8%), Other Businesses ¥1,057 million (YoY +6.0%)
Segment profitCosmetics Business ¥5,357 million (YoY -16.5%), Pharmaceuticals and food business ¥389 million (YoY -8.5%), Other Businesses ¥59 million (YoY -41.6%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥65,000 million (YoY +0.4%)
Operating profit¥11,400 million (YoY +2.9%)
Ordinary income¥11,800 million (YoY +0.2%)
Net income¥8,200 million (YoY +2.1%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥230 → ¥230(0.0%)
Factors Behind Changes in Business Performance

Although the economy showed signs of a gradual recovery, conditions remained uncertain due to factors including the impact of the situation in the Middle East. The company worked on the medium- to long-term strategic theme of "achieving disciplined growth through sustainable management of each business in the Group."

Disclosure regarding the going concern assumption

No applicable matters ("There are no applicable matters")

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name Not disclosed
Impairment loss¥120 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥922 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥0 million, Impairment Losses ¥120 million, Loss on cancellation of insurance policies ¥164 million
Depreciation and amortization¥476 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End34,156,623
Treasury Shares at Period-End416
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 October 2025–31 March 2026
Net Sales¥30,615 million (YoY -4.4%)
Operating profit¥4,534 million (YoY -20.6%)
Ordinary income¥4,789 million (YoY -20.5%)
Profit attributable to owners of the parent¥2,718 million (YoY +2.9%)
Net income per share¥79.59
Equity ratioEnd of the current fiscal period 68.1 / End of previous period 70.3
Total assets¥71,736 million
Net assets¥49,489 million
Cash flows from operating activities¥3,080 million
Cash flows from investing activities¥1,063 million
Cash flows from financing activities¥-7,895 million
Cash and cash equivalents at end of period¥23,215 million
Full-year earnings forecastNet Sales ¥65,000 million (YoY +0.4%) / Operating profit ¥11,400 million (YoY +2.9%) / Ordinary income ¥11,800 million (YoY +0.2%) / Net income ¥8,200 million (YoY +2.1%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥230 → ¥230(0.0%)
Segment revenueCosmetics Business ¥24,173 million (YoY -5.0%), Pharmaceuticals and food business ¥5,385 million (YoY -3.8%), Other Businesses ¥1,057 million (YoY +6.0%)
Segment profitCosmetics Business ¥5,357 million (YoY -16.5%), Pharmaceuticals and food business ¥389 million (YoY -8.5%), Other Businesses ¥59 million (YoY -41.6%)
Depreciation and amortization¥476 million
Impairment loss¥120 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥922 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥0 million, Impairment Losses ¥120 million, Loss on cancellation of insurance policies ¥164 million
Disclosure regarding the going concern assumptionNo applicable matters ("There are no applicable matters")
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name Not disclosed
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End34,156,623
Treasury Shares at Period-End416
Factors Behind Changes in Business PerformanceAlthough the economy showed signs of a gradual recovery, conditions remained uncertain due to factors including the impact of the situation in the Middle East. The company worked on the medium- to long-term strategic theme of "achieving disciplined growth through sustainable management of each business in the Group."
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that although the economy showed signs of a gradual recovery, uncertainty persisted due to factors including the impact of the situation in the Middle East. It also stated that it worked on the medium- to long-term strategic theme of "achieving disciplined growth through sustainable management of each business in the Group."

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending September 2026 [Japanese GAAP] (Consolidated) | Noevir Holdings Co.,Ltd. (4928) timely disclosure | Komori